151908-49-5

Upstream product

• 148766-15-8 (R,E)-3-but-2-enoyl-4-phenyloxazolidin-2-one 
• 151800-31-6 (3(3S),4R)-3-<3-(4'-Methoxyphenyl)butanoyl>-4-phenyl-2-oxazolidinone 
• 90319-52-1 (4R)-phenyl-2-oxazolidinone 
• 104-92-7 1-bromo-4-methoxy-benzene 

Downstream Products

• 758685-22-2 (2S,3R)-2-Amino-3-(4-methoxy-phenyl)-butyric acid 
• 128573-12-6 threo-L-(2S,3R)-β-Methyltyrosine 
• 151800-34-9 (2S,3R)-2-Azido-3-(4-methoxyphenyl)butyric acid 

Relevant academic research and scientific papers

UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.

Efficient Method for the Total Asymmetric Synthesis of the Isomers of β-Methyltyrosine

α-Amino acids modified at the β-carbon atom can provide topographical constraints when incorporated into a peptide.Such modifications can modulate the physical, chemical, and biological properties of the compound.In order to properly evaluate the effect o